Neovasc Inc. announced the US Food and Drug Administration (FDA) has granted approval for participating physicians to treat patients with its 40mm Tiara valve in the company's TIARA-I Early Feasibility Trial. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial being conducted at centers in the US, Europe and Canada to assess the safety and performance of Neovasc's Tiara™ Mitral Valve System and implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation (MR).